Hepatocellular carcinoma (HCC) is a globally relevant medical problem. Fortunately, risk factors for this tumor have been identified, and surveillance protocols developed. Patients with liver cirrhosis have the highest risk of developing HCC and have historically been included in surveillance programs. Special categories have also emerged in recent years, especially patients with eradicated HCV infection or nonalcoholic fatty liver disease. Novel serum biomarkers and magnetic resonance imaging protocols are currently being proposed to refine existing surveillance protocols.
Stefanini B., Tonnini M., Serio I., Renzulli M., Tovoli F. (2022). Surveillance for hepatocellular carcinoma: current status and future perspectives for improvement. EXPERT REVIEW OF ANTICANCER THERAPY, 22(4), 371-381 [10.1080/14737140.2022.2052276].
Surveillance for hepatocellular carcinoma: current status and future perspectives for improvement
Stefanini B.;Tonnini M.;Serio I.;Renzulli M.;Tovoli F.
2022
Abstract
Hepatocellular carcinoma (HCC) is a globally relevant medical problem. Fortunately, risk factors for this tumor have been identified, and surveillance protocols developed. Patients with liver cirrhosis have the highest risk of developing HCC and have historically been included in surveillance programs. Special categories have also emerged in recent years, especially patients with eradicated HCV infection or nonalcoholic fatty liver disease. Novel serum biomarkers and magnetic resonance imaging protocols are currently being proposed to refine existing surveillance protocols.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
